BRONCUS-B (02216) announced that on December 29, 2025, its wholly-owned subsidiary, Broncus China Holding Corporation, intends to acquire 157,800 Series B preferred shares of Valgen Holding Corporation from Venus Medtech (Hong Kong) Co., Ltd. This represents 1.05% of the target company's issued and outstanding shares on a fully diluted and as-converted basis as of the announcement date, for a total consideration of $15 million. The target group is primarily engaged in providing systemic solutions for conditions such as mitral regurgitation and tricuspid regurgitation. Its product portfolio includes the DragonFly™ mitral valve repair device (transfemoral approach) and the DragonFly-TTM tricuspid valve repair device. Given the similarities and interconnections between structural heart disease and pulmonary diseases, the Board believes the acquisition presents a valuable opportunity for the Group to achieve integrated diagnosis and treatment of cardiopulmonary diseases. Leveraging the company's expertise in chronic obstructive pulmonary disease (COPD), collaboration with the target group will enable the Group to lay a solid foundation for establishing a comprehensive platform for the diagnosis and treatment of cardiopulmonary diseases. Furthermore, as the treatment of both structural heart disease and pulmonary diseases involves interventional therapies, the acquisition also provides the Group with an opportunity to enhance its R&D capabilities by applying its structural heart disease treatment technologies to pulmonary diseases, and vice versa.